Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients

Jongmin Lee119 enrolled

Overview

This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.

Study Type

OBSERVATIONAL

Enrollment

119

Conditions

Sepsis Immune Deficiency

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged ≥ 19 years * Appropriate clinical data to enable classification into sepsis * Written informed consent by the patient or legally authorized representative * Critical illness consistent with sepsis, to be enrolled within 24 hours of presentation Exclusion Criteria: * No informed consent * A patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability

Locations (1)

Seoul St. Mary's Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between immunocompetent and immunocompromised patients.

For the analysis, plasma presepsin levels on Day 0 will be used. Sepsis was made on Day 7 or day of discharge. ROC-AUC of presepsin for discriminating between immunocompromised and immunocompetent patients is compared to that of procalcitonin.

Time frame: up to 7 days

Secondary Outcomes

survival at ICU discharge or day 28 after enrollment

For the analysis, we will evaluate the association between presepsin and survival at ICU discharge or day 28 after enrollment

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.